Treatment of Parkinson's disease in Spain.
To assess the patterns of drug use in Parkinson's disease in Spain, information about the clinical characteristics and current treatment of 1803 parkinsonian patients was obtained from a nationwide survey, involving 241 physicians with practice based on the different assistance levels of the Spanish National Healthcare System. Approximately 90% of the patients were treated with levodopa, regardless of the characteristics of their physicians, but the use of the other available antiparkinsonian treatments was highly influenced by the medical specialty and interest in movement disorders of the prescribing doctors.
Grandas
Francisco
F
Servicio de Neurología, Hospital General Universitario Gregorio Marañón, Madrid, Spain. fgrandasp@meditex.es
Kulisevsky
Jaime
J
D000328:Adult; D000368:Aged; D000978:Antiparkinson Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003430:Cross-Sectional Studies; D004363:Drug Utilization / Q000706:statistics & numerical data; D005260:Female; D006306:Health Surveys; D006801:Humans; D007980:Levodopa / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy* / Q000453:epidemiology; D010348:Patient Care Team / Q000706:statistics & numerical data; D013030:Spain / Q000453:epidemiology
D000978:Antiparkinson Agents; D007980:Levodopa